![ECOG-ACRIN logo[19516]275x75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
Leukemia
September 30, 2021
A focus on leukemia trials; an update regarding advanced practice providers; two important topics related to patient communication
September 30, 2021
This phase Ib/II study is testing the effects and safety of venetoclax in combination with liposomal vincristinein patients with B-ALL or T-ALL
September 30, 2021
This phase II trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity
March 31, 2021
The EA9171 phase II trial aims to determine if adding pembrolizumab immunotherapy to standard-of-care TKI therapy helps more patients achieve undetectable minimal residual disease and allows them to discontinue TKI therapy
December 14, 2020
The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
January 14, 2020
